Note Year ended Dec 2024 $’000 Year ended Dec 2023 $’000 Revenue from contracts with customers 6 213,243 231,925 Finance income 11,014 5,687 Gain on financial derivatives measured at fair value through profit and loss 3,587 – Net foreign currency gain – 2,434 Other income 2 17 Total income 227,846 240,063 Expenses Research and development costs (32,970) (26,751) Corporate and administrative costs (4,701) (5,946) Loss on financial derivatives measured at fair value through profit and loss – (2,226) Net foreign currency loss (7,235) – Total expenses (44,906) (34,923) Profit before income tax expense 182,940 205,140 Income tax expense 8 (40,897) (48,059) Profit after income tax expense for the year attributable to the owners of Neuren Pharmaceuticals Limited 142,043 157,081 Other comprehensive income Items that may be reclassified subsequently to profit or loss Foreign currency translation 24,198 (10) Other comprehensive income for the year, net of tax 24,198 (10) Total comprehensive income for the year attributable to the owners of Neuren Pharmaceuticals Limited 166,241 157,071 Cents Cents Basic earnings per share 9 111.17 123.62 Diluted earnings per share 9 108.61 120.12 CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME FOR THE YEAR ENDED 31 DECEMBER 2024 The above consolidated statement of profit or loss and other comprehensive income should be read in conjunction with the accompanying notes Neuren Pharmaceuticals Limited Annual Report 2024 24
RkJQdWJsaXNoZXIy MjE2NDg3